Cl-IB-MECA [2-Chloro-N6-(3-iodobenzyl)adenosine-5′-N-methylcarboxamide] Reduces Ischemia/Reperfusion Injury in Mice by Activating the A Adenosine Receptor
- 1 December 2006
- journal article
- Published by Elsevier in The Journal of Pharmacology and Experimental Therapeutics
- Vol. 319 (3) , 1200-1210
- https://doi.org/10.1124/jpet.106.111351
Abstract
We used pharmacological agents and genetic methods to determine whether the potent A(3) adenosine receptor (AR) agonist 2-chloro-N(6)-(3-iodobenzyl)adenosine-5'-N-methylcarboxamide (Cl-IB-MECA) protects against myocardial ischemia/reperfusion injury in mice via the A(3)AR or via interactions with other AR subtypes. Pretreating wild-type (WT) mice with Cl-IB-MECA reduced myocardial infarct size induced by 30 min of coronary occlusion and 24 h of reperfusion at doses (30 and 100 mug/kg) that concomitantly reduced blood pressure and stimulated systemic histamine release. The A(3)AR-selective antagonist MRS 1523 [3-propyl-6-ethyl-5[(ethylthio)carbonyl]-2-phenyl-4-propyl-3-pyridine-carboxylate], but not the A(2A)AR antagonist ZM 241385 [4-{2-7-amino-2-(2-furyl)[1,2,4]triazolo-[2,3-a][1,3,5]triazin-5-ylamino]ethyl}phenol], blocked the reduction in infarct size provided by Cl-IB-MECA, suggesting a mechanism involving the A(3)AR. To further examine the selectivity of Cl-IB-MECA, we assessed its cardioprotective effectiveness in A(3)AR gene "knock-out" (A(3)KO) mice. Cl-IB-MECA did not reduce myocardial infarct size in A(3)KO mice in vivo and did not protect isolated perfused hearts obtained from A(3)KO mice from injury induced by global ischemia and reperfusion. Additional studies using WT mice treated with compound 48/80 [condensation product of p-methoxyphenethyl methylamine with formaldehyde] to deplete mast cell contents excluded the possibility that Cl-IB-MECA was cardioprotective by releasing mediators from mast cells. These data demonstrate that Cl-IB-MECA protects against myocardial ischemia/reperfusion injury in mice principally by activating the A(3)AR.This publication has 29 references indexed in Scilit:
- Adenosine Inhibits Tumor Necrosis Factor-α Release from Mouse Peritoneal Macrophages via A2A and A2B but Not the A3 Adenosine ReceptorThe Journal of Pharmacology and Experimental Therapeutics, 2006
- Adenosine A2Aagonists in development for the treatment of inflammationExpert Opinion on Investigational Drugs, 2005
- Gene Dosage-Dependent Effects of Cardiac-Specific Overexpression of the A 3 Adenosine ReceptorCirculation Research, 2002
- Effects of A3 adenosine receptor activation and gene knock-out in ischemic-reperfused mouse heartCardiovascular Research, 2002
- Protection of IB-MECA against myocardial stunning in conscious rabbits is not mediated by the A1 adenosine receptorBasic Research in Cardiology, 2001
- Targeted Deletion of the A3Adenosine Receptor Confers Resistance to Myocardial Ischemic Injury and does not Prevent Early PreconditioningJournal of Molecular and Cellular Cardiology, 2001
- Canine Mast Cell Adenosine Receptors: Cloning and Expression of the A3 Receptor and Evidence that Degranulation Is Mediated by the A2B ReceptorMolecular Pharmacology, 1997
- Selective Activation of A 3 Adenosine Receptors With N 6 -(3-Iodobenzyl)Adenosine-5′- N -Methyluronamide Protects Against Myocardial Stunning and Infarction Without Hemodynamic Changes in Conscious RabbitsCirculation Research, 1997
- Mast cell degranulation following adenosine A3 receptor activation in ratsEuropean Journal of Pharmacology, 1996
- A role for mast cells in adenosine A3 receptor‐mediated hypotension in the ratBritish Journal of Pharmacology, 1995